Original news and analysis on international IP policy
After the failure to agree on work to be done by the World Intellectual Property Organization committee on genetic resources and traditional knowledge at the last general assembly, and a barren calendar of meetings on the subject, WIPO is organising a seminar aimed at sharing regional, national and local experiences.
The next meeting of the World Trade Organization intellectual property committee is expected to include discussions on women and innovation, and concerns about legislative efforts in the United Kingdom and Ireland to introduce plan packaging for tobacco products. Prior to the meeting, informal consultations will be held on the negotiating issue of an international register for geographical indications (GIs) for wines and spirits.
Intellectual property-related developments expected this year could profoundly impact the fields of biotechnology and biodiversity. In addition, ongoing issues relating to plant variety protection and public health are expected to be at the forefront of discussions this year. The following is a look at many of the top issues to come.
The biotechnology industry is closely watching developments in the United States that could impact the industry in 2015. These include the regulatory framework for biosimilars, possible patent legislation, post-grant review procedure, and the consequences of the recent Supreme Court ruling banning the patenting of human genes. Hans Sauer, Deputy General Counsel for Intellectual Property at the Biotechnology Industry Organization (BIO), recently spoke with Intellectual Property Watch’s Catherine Saez. Sauer was asked to lay out the main developments to watch in the coming year.
The World Health Organization Executive Board this week recommended the extension of an important strategy and plan of action on health, IP and innovation. It also set out steps to resolve questions over evaluation and review of the strategy and plan of action before the annual World Health Assembly in May.
In search of sustainable innovation models for cures for diseases affecting primarily developing countries, with the Ebola epidemic as a new reminder of the necessity and urgency of the matter, the World Health Organization had tasked an expert working group with the search for solutions. Last week, the WHO Executive Board took note of the progress made so far.
Intellectual property issues emerged at the World Health Organization Executive Board today as members discussed fake and substandard medicines, with some countries saying that the fight against such medicines should not serve as a pretext to enforce intellectual property rights and prevent access to safe generic medicines.
The World Health Organization Executive Board this week has addressed the relationship between the UN agency and its funders and lobbyists, examined the budget for the next biennium, and looked at the issue of the growing resistance of bacteria to…
Gavi, the Vaccine Alliance, boasted success this week as its biennial replenishment conference attracted US$ 7.5 billion in pledges, which is the organisation said is expected to allow 300 million additional children to be vaccinated in poor countries. The vaccine…
At the World Health Organization Executive Board today, a group of countries tabled a proposal to extend the WHO plan of action on public health, innovation and intellectual property until 2022. Yesterday, the Executive Board took note of the Global Vaccine Action Plan while some countries remarked on issues of affordability and accessibility. And today, one of the key discussions of the week - on the engagement of WHO with lobbyists, donors, and other interested non-governmental parties - has begun.
The World Health Organization Executive Board yesterday adopted a resolution on Ebola, on the eve of today’s opening of its 10-day meeting addressing a broad range of health issues, including several of relevance to the intellectual property and innovation community. Today, Italy requested that member states be involved in the setting of WHO guidelines, raising governance issues, while WHO Director General Margaret Chan called for strong health systems and reform to the WHO structure, and asked for room to move on WHO relations with industry.
Biosimilars are a hot topic. Beyond the colossal profits foreseen by some, drawing a lot of interested parties into the game, developing countries mean to play a role in this new frontier. However, biosimilars - close copies of biopharmaceutical products - are difficult and very costly to produce and come as a challenge to the generic industry used to duplicating small molecules. And some warn about differences in regulatory requirements, which could effectively boot developing countries out of the global market.